FOXO4-DRI vs Tesofensine
Compare the research profiles of FOXO4-DRI and Tesofensine. Read the individual guides for evidence and limitations.
How to interpret this comparison
This page summarizes database profiles and has not yet received a study-by-study editorial review. These compounds are filed under different research categories, so a direct treatment comparison may not answer a meaningful clinical question. Use the linked guides and primary sources to evaluate a specific claim.
How to read peptide studiesFOXO4-DRI
FOXO4-D-Retro-Inverso
senolytic
Preclinical
not-approved
Tesofensine
Tesofensine
weight-loss
Phase 3 Clinical Trials
clinical-trials
Detailed Comparison
| Aspect | FOXO4-DRI | Tesofensine |
|---|---|---|
| Overview | A promising senolytic peptide being researched for its potential to clear senescent ("zombie") cells to reverse aspects of biological aging. Showed dramatic results in aged mice.... | A triple monoamine reuptake inhibitor rising fast in popularity for its potent appetite suppression capabilities. Originally developed for Parkinson's and Alzheimer's, now being studied for obesity.... |
| Research topics (not established benefits) |
|
|
| Side Effects |
|
|
| Mechanism | Disrupts the interaction between FOXO4 and p53 in senescent cells, triggering apoptosis (cell death) specifically in these damaged cells while leaving... | Inhibits reuptake of norepinephrine, dopamine, and serotonin, leading to reduced appetite and increased energy expenditure. Works on brain chemistry r... |
Frequently Asked Questions
Does a comparison establish which treatment is better?
Only appropriately designed evidence for the same clinical question can support that conclusion. Database categories and mechanisms alone cannot rank treatments.
Does this page establish that these compounds can be combined?
No. This page does not assess interactions or the benefit and safety of combined use. Individual studies cannot establish the effects of a combination.